WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation

Research summary

The Champion AF study is designed to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to Direct Oral Anticoagulant (NOACs) in patients with non-valvular atrial fibrillation. Patients in this study will be randomized to either receive the WATCHMAN FLX Device or a course of NOACs patients will be assessed over a period of up to 5 years.

Principal Investigator

Prof Tim Betts

Contact us

Email: oxfordheartresearch@ouh.nhs.uk

IRAS number

287122